ABUS News and Press, Arbutus Biopharma Corporation From 02/08/24

2024-02-08 17:13:43 ET Gainers: Farmer Brothers  ( FARM ) +15% . Corvus Pharmaceuticals  ( CRVS ) +10% . Impinj ( PI ) +9% . CalAmp ( CAMP ) +6% . Arbutus Biopharma Corporation ( ABUS ) +6% . Losers: Affirm Hold...

2024-01-09 09:00:00 ET Summary Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts i...

2024-01-08 12:31:33 ET More on Arbutus Biopharma Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript Putting Arbutus Biopharma Back In The Spotlight Arbutus Biopharma GAAP EPS of -$0.12 misses by $0.01, revenue of $4.66M misses by $0.06M, reduces 24...

Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a third Phase 2a clinical trial evaluating imdusiran and an approved PD-L1 monoclonal antibody...

2023-12-04 16:36:31 ET Gainers: GitLab  ( GTLB ) +16% . EyePoint Pharmaceuticals ( EYPT ) +6% . Travere Therapeutics ( TVTX ) +3% . AST SpaceMobile ( ASTS ) +3% . Arbutus Biopharma Corporation ( ABUS ) +2% . Losers: ...

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well...

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation WARMINSTER, Pa. and OXFORD, United Kingdom, ...

2023-11-07 11:06:05 ET Arbutus Biopharma Corporation. (ABUS) Q3 2023 Earnings Conference Call November 07, 2023, 08.45 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO and CAO Karen Sims - Ch...

2023-11-07 08:47:44 ET More on Arbutus Biopharma Putting Arbutus Biopharma Back In The Spotlight Alnylam sends Arbutus lower after FDA snub for amyloidosis drug For further details see: Arbutus Biopharma says its CEO William Collier will retire

2023-11-07 07:36:28 ET More on Arbutus Biopharma Putting Arbutus Biopharma Back In The Spotlight Arbutus Biopharma Corporation 2023 Q2 - Results - Earnings Call Presentation Alnylam sends Arbutus lower after FDA snub for amyloidosis drug Arbutus ends developm...